AU2017319707B2 - Genetically modified bacteria stably expressing IL-10 and insulin - Google Patents

Genetically modified bacteria stably expressing IL-10 and insulin Download PDF

Info

Publication number
AU2017319707B2
AU2017319707B2 AU2017319707A AU2017319707A AU2017319707B2 AU 2017319707 B2 AU2017319707 B2 AU 2017319707B2 AU 2017319707 A AU2017319707 A AU 2017319707A AU 2017319707 A AU2017319707 A AU 2017319707A AU 2017319707 B2 AU2017319707 B2 AU 2017319707B2
Authority
AU
Australia
Prior art keywords
responder
foxp3
cells
lab
onset
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2017319707A
Other languages
English (en)
Other versions
AU2017319707A1 (en
Inventor
Pieter Rottiers
Lothar Steidler
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Intrexon Actobiotics NV
Original Assignee
Intrexon Actobiotics NV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrexon Actobiotics NV filed Critical Intrexon Actobiotics NV
Publication of AU2017319707A1 publication Critical patent/AU2017319707A1/en
Application granted granted Critical
Publication of AU2017319707B2 publication Critical patent/AU2017319707B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • C12N15/746—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora for lactic acid bacteria (Streptococcus; Lactococcus; Lactobacillus; Pediococcus; Enterococcus; Leuconostoc; Propionibacterium; Bifidobacterium; Sporolactobacillus)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5428—IL-10
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/62—Insulins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AU2017319707A 2016-09-02 2017-09-02 Genetically modified bacteria stably expressing IL-10 and insulin Active AU2017319707B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662383079P 2016-09-02 2016-09-02
US62/383,079 2016-09-02
PCT/IB2017/055287 WO2018042390A1 (en) 2016-09-02 2017-09-02 Genetically modified bacteria stably expressing il-10 and insulin

Publications (2)

Publication Number Publication Date
AU2017319707A1 AU2017319707A1 (en) 2019-03-07
AU2017319707B2 true AU2017319707B2 (en) 2023-11-09

Family

ID=60120085

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2017319707A Active AU2017319707B2 (en) 2016-09-02 2017-09-02 Genetically modified bacteria stably expressing IL-10 and insulin

Country Status (8)

Country Link
US (3) US10858663B2 (https=)
EP (1) EP3506932B1 (https=)
JP (3) JP7016865B2 (https=)
CN (2) CN109843320A (https=)
AU (1) AU2017319707B2 (https=)
CA (1) CA3035151A1 (https=)
RU (1) RU2768027C2 (https=)
WO (1) WO2018042390A1 (https=)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7016865B2 (ja) * 2016-09-02 2022-03-03 イントレクソン・アクトバイオテイクス・エヌブイ Ｉｌ－１０およびインスリンを安定的に発現する遺伝子改変された細菌
CN109983028B (zh) 2016-09-13 2023-10-20 英特瑞克斯顿阿克图比奥帝克斯有限公司 黏膜黏附性微生物
EP4582440A3 (en) * 2018-12-21 2025-10-08 The Regents of the University of California Il-10-containing vaccines and uses thereof
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
WO2024146463A1 (zh) * 2023-01-03 2024-07-11 深圳先进技术研究院 分泌白介素-10的细菌
CN116726158A (zh) * 2023-04-24 2023-09-12 中国医学科学院医学生物学研究所 一种多表位1型糖尿病疫苗及其制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063075A1 (en) * 2005-11-29 2007-06-07 Actogenix Nv Induction of mucosal tolerance to antigens

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB227835A (en) 1924-01-15 1925-04-09 Harry Odell Improvements in feeding mechanism for embossing and other printing presses
US4919918A (en) 1988-03-14 1990-04-24 Spectrum Consumer Products Co., Inc. Non-alcoholic mouthwash
US5972685A (en) 1988-07-21 1999-10-26 Iowa State University Research Foundation, Inc. Oral administration of coprostanol producing microorganisms to humans to decrease plasma cholesterol concentration
GB9126306D0 (en) 1991-12-11 1992-02-12 Unilever Plc Mouthwash compositions
JPH07504815A (ja) 1992-02-27 1995-06-01 マイクロバイアル　テクニクス　リミティド 乳酸菌における異種遺伝子の発現およびその発現産物
US5223285A (en) 1992-03-31 1993-06-29 Abbott Laboratories Nutritional product for pulmonary patients
US5700782A (en) 1993-05-28 1997-12-23 Abbott Laboratories Enteral nutritional product
WO1996032486A1 (en) 1995-04-11 1996-10-17 Nederlandse Organisatie Voor Toegepast-Natuurwetenschappelijk Onderzoek Tno Method for the construction of vectors for lactic acid bacteria like lactobacillus such that the bacteria can efficiently express, secrete and display proteins at the surface
US5695746A (en) 1995-07-28 1997-12-09 Chesebrough-Pond's Usa Co., Division Of Conopco, Inc. Liquid dentifrice with mouthwash fresh taste
WO1997026855A1 (en) 1996-01-24 1997-07-31 Warner-Lambert Company Peroxide/essential oils containing mouthwash compositions and two-part mouthwash systems
GB9611364D0 (en) 1996-05-31 1996-08-07 Smithkline Beecham Plc Composition
PT939613E (pt) 1996-09-18 2003-07-31 Erling Johansen Solucao sobressaturada para lavagem bucal contendo ioes calcio e fosfato
US5869118A (en) 1996-11-13 1999-02-09 Abbott Laboratories Gellan gum to improve physical stability of liquid nutritional products
US5897872A (en) 1997-11-12 1999-04-27 Picciano; Dante J. Iodine-containing nasal moisturizing saline solution
US6171611B1 (en) 1997-11-12 2001-01-09 Dante J. Picciano Iodine-containing nasal moisturizing saline and mouthwash solutions
JP5068401B2 (ja) 1998-09-28 2012-11-07 カプスゲル・ベルギウム・ナムローゼ・フェンノートシャップ Ｈｐｍｃカプセルを使用する腸及び結腸への送達
AU1071200A (en) 1998-10-19 2000-05-08 Biotech Australia Pty Limited Systems for oral delivery
WO2002090551A2 (en) 2001-05-03 2002-11-14 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Self-containing lactococcus strain
US20040043003A1 (en) * 2002-01-31 2004-03-04 Wei Chen Clinical grade vectors based on natural microflora for use in delivering therapeutic compositions
US20040076590A1 (en) 2002-07-08 2004-04-22 Wilkins Joe S. Antibacterial toothpaste and mouthwash formulations
WO2004056850A2 (en) * 2002-12-19 2004-07-08 Vib Vzw Mutant proteins showing increased secretion
EP2115146B1 (en) 2007-01-12 2016-07-06 Intrexon Actobiotics NV Lactococcus promoters and uses thereof
CN103933563B (zh) 2007-01-25 2016-09-28 英特瑞克斯顿阿克图比奥帝克斯有限公司 使用遗传修饰的乳杆菌通过抗原的粘膜递送治疗免疫疾病
BRPI0809448A2 (pt) * 2007-03-28 2014-09-09 Alimentary Health Ltd Cepas de bifidobacterium probióticas
JP5572972B2 (ja) * 2009-03-16 2014-08-20 Ｊｎｃ株式会社 インスリン分泌促進剤などの薬物のスクリーニング方法
WO2010124855A1 (en) 2009-04-30 2010-11-04 Actogenix Nv Cryoprotectants for freeze drying of lactic acid bacteria
WO2012164083A1 (en) * 2011-06-01 2012-12-06 Actogenix N.V. Polycistronic expression system for bacteria
EP3382006B1 (en) * 2011-09-23 2021-02-17 Intrexon Actobiotics NV Modified gram positive bacteria and uses thereof
WO2013041672A1 (en) * 2011-09-23 2013-03-28 Actogenix Nv Modified gram positive bacteria and uses thereof
JP7016865B2 (ja) * 2016-09-02 2022-03-03 イントレクソン・アクトバイオテイクス・エヌブイ Ｉｌ－１０およびインスリンを安定的に発現する遺伝子改変された細菌

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007063075A1 (en) * 2005-11-29 2007-06-07 Actogenix Nv Induction of mucosal tolerance to antigens

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TATIANA TAKIISHI ET AL: JOURNAL OF CLINICAL INVESTIGATION, vol. 122, no. 5, 1 May 2012 (2012-05-01), US, pages 1717 - 1725, XP055308282, ISSN: 0021-9738, DOI: 10.1172/JCI60530 *

Also Published As

Publication number Publication date
JP2024047590A (ja) 2024-04-05
CN118813511A (zh) 2024-10-22
JP2019526262A (ja) 2019-09-19
US12359210B2 (en) 2025-07-15
EP3506932B1 (en) 2025-06-25
EP3506932A1 (en) 2019-07-10
JP2022061035A (ja) 2022-04-15
CN109843320A (zh) 2019-06-04
RU2019104948A (ru) 2020-10-02
US11549118B2 (en) 2023-01-10
US20190292551A1 (en) 2019-09-26
RU2768027C2 (ru) 2022-03-23
RU2019104948A3 (https=) 2020-12-23
CA3035151A1 (en) 2018-03-08
WO2018042390A1 (en) 2018-03-08
AU2017319707A1 (en) 2019-03-07
US20210180072A1 (en) 2021-06-17
JP7016865B2 (ja) 2022-03-03
US10858663B2 (en) 2020-12-08
US20230348918A1 (en) 2023-11-02

Similar Documents

Publication Publication Date Title
US12246046B2 (en) Compositions and methods for the treatment of type 1 diabetes
US12359210B2 (en) Genetically modified bacteria stably expressing IL-10 and insulin
US20220340621A1 (en) Treatment of celiac disease
HK40065260A (en) Compositions and methods for the treatment of type 1 diabetes
HK40065260B (en) Compositions and methods for the treatment of type 1 diabetes
HK1262225B (en) Compositions and methods for the treatment of type 1 diabetes

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)